Literature DB >> 21034415

New strategies and patent therapeutics in EBV-associated diseases.

E Villegas1, O Santiago, A Sorlózano, J Gutierrez.   

Abstract

Epstein-Barr virus (EBV) is a virus present all throughout the world that causes infectious mononucleosis (IM) and is highly associated with certain malignancies. This study is a review of current knowledge concerning the pathogenic mechanisms of EBV in tumor and auto-immune diseases and the different new strategies to treat EBV associated pathologies. Phenomena surrounding the proliferation and immortalization of B lymphocytes, the mechanisms of immune escape and the role of CD8+ and CD4+ T cells in the infection by EBV are explained. An analysis is made of the role of EBV proteins during the biological events that take place in primary infection, persistent chronic infection together with an update of the approaches of novel patented therapeutics. Currently there is no vaccine protecting against EBV-associated disorders and no treatment that may inhibit or eliminate their progression. Thus, it is crucial to obtain additional information on the function and importance of genes that play a role on the development of those diseases with which it is associated, as well as on the humoral and cellular immune processes involved in them.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21034415     DOI: 10.2174/138955710792007150

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  3 in total

1.  Immunization with Epstein-Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge.

Authors:  Xinle Cui; Zhouhong Cao; Yuriko Ishikawa; Sara Cui; Ken-Ichi Imadome; Clifford M Snapper
Journal:  Vaccines (Basel)       Date:  2021-03-19

2.  Epstein-Barr Virus-Positive Langerhans Cell Sarcoma: Is There a Link? A Case Report.

Authors:  Yu Guo; Shui-Hong Zhou; Zai-Zai Cao; Yang-Yang Bao; Li-Fang Shen; Hong-Tian Yao
Journal:  Front Oncol       Date:  2022-01-18       Impact factor: 6.244

Review 3.  Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.

Authors:  Xinle Cui; Clifford M Snapper
Journal:  Front Immunol       Date:  2021-10-08       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.